Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | GPR183 | P32249 | 8/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344182 | 1.00 | RAB9A (0.65) | RAB9ASMN1; SMN2GAANPC1TDP1 | |
| SCHEMBL1556407 | 0.89 | RAB9A (0.62) | RAB9ASMN1; SMN2GAANPC1TDP1 | |
| SCHEMBL1556410 | 0.89 | RAB9A (0.62) | RAB9ASMN1; SMN2GAANPC1TDP1 | |
| SCHEMBL1341698 | 0.85 | SMN1; SMN2 (0.69) | RAB9ASMN1; SMN2GAANPC1GPR183 | |
| SCHEMBL1341697 | 0.85 | SMN1; SMN2 (0.69) | RAB9ASMN1; SMN2GAANPC1GPR183 | |
| SCHEMBL22633478 | 0.80 | RAB9A (0.58) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL22633477 | 0.80 | RAB9A (0.58) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL2897130 | 0.80 | RAB9A (0.54) | RAB9ASMN1; SMN2GAANPC1TDP1 | |
| SCHEMBL2899264 | 0.79 | RAB9A (0.52) | RAB9ASMN1; SMN2GAANPC1TDP1 | |
| SCHEMBL2899267 | 0.79 | RAB9A (0.52) | RAB9ASMN1; SMN2GAANPC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2220055-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2009010429-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | RAB9A 914/4885SMN1; SMN2 4301/4885GAA 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.